A randomised, double-blinded, placebo-controlled trial using cardiovascular magnetic resonance (CMR) scanning to assess remodelling and regression of fibrosis in cardiomyopathy with eplerenone
ISRCTN | ISRCTN23314770 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN23314770 |
Secondary identifying numbers | N0201163398 |
- Submission date
- 28/09/2007
- Registration date
- 28/09/2007
- Last edited
- 12/10/2017
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Sanjay K Prasad
Scientific
Scientific
Royal Brompton & Harefield NHS Trust
Sydney Street
London
SW3 6NP
United Kingdom
Phone | +44 (0)20 7351 8194 |
---|---|
s.prasad@rbh.nthames.nhs.uk |
Study information
Study design | Randomised double-blinded placebo-controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet |
Scientific title | A randomised, double-blinded, placebo-controlled trial using cardiovascular magnetic resonance (CMR) scanning to assess remodelling and regression of fibrosis in cardiomyopathy with eplerenone |
Study objectives | To demonstrate regression of fibrosis in patients with cardiomyopathy who are treated with eplerenone using cardiovascular magnetic resonance. This trial compares patients taking the drug eplerenone with patients who don't and whether it reduces the amount of fibrosis (scarring) of the heart. |
Ethics approval(s) | Riverside Research Ethics Committee Charing Cross Hospital (UK), 09/10/2006, ref 06/Q0401/50 |
Health condition(s) or problem(s) studied | Cardiovascular: Cardiomyopathy |
Intervention | Eplerenone vs placebo |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Not Applicable |
Drug / device / biological / vaccine name(s) | Eplerenone |
Primary outcome measure | Reduction in amount of fibrosis as determined by CMR Late enhancement |
Secondary outcome measures | 1. Improvement in myocardial oxygen consumption (MVO2) 2. Reduction in major adverse cardiovascular events |
Overall study start date | 27/10/2006 |
Completion date | 26/10/2008 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Sex | Both |
Target number of participants | 140 |
Key inclusion criteria | Stable patients with an established diagnosis of cardiomyopathy as assessed by history, examination and typical ECG/Echo findings who are on maximally tolerated doses of appropriate drugs with no changes being made to the prescription in the 2 months preceding the start of the trial. |
Key exclusion criteria | 1. Patients already established on treatment with an aldosterone antagonist 2. Patients with contraindications to eplerenone (hyperkalaemia, renal failure) 3. Critically ill patients requiring respiratory and/or circulatory support 4. Pacemaker or ICD 5. Implanted ferromagnetic cerebrovascular clips 6. Pregnant women (precautionary only) 7. Intolerance of confined spaces 8. Inability to lie supine for 60 minutes 9. Unwilling or unable to give written informed consent 10.Atrial fibrillation or ventricular bigeminy 11. Any contraindication to CMR. 12. Recent MI 13. HCM patients who have received surgical/alcohol ablation treatment |
Date of first enrolment | 27/10/2006 |
Date of final enrolment | 26/10/2008 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Royal Brompton & Harefield NHS Trust
London
SW3 6NP
United Kingdom
SW3 6NP
United Kingdom
Sponsor information
Record Provided by the NHSTCT Register - 2007 Update - Department of Health
Government
Government
The Department of Health, Richmond House, 79 Whitehall
London
SW1A 2NL
United Kingdom
Phone | +44 (0)20 7307 2622 |
---|---|
dhmail@doh.gsi.org.uk | |
Website | http://www.dh.gov.uk/Home/fs/en |
Funders
Funder type
Government
Royal Brompton and Harefield NHS Trust (UK), No External Funding, NHS R&D Support Funding
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Editorial Notes
12/10/2017: No publications found, verifying study status with principal investigator.